Successful IVIG treatment without discontinuation of TNF-α blocker in Guillain-Barre syndrome induced by adalimumab in patient with Crohn's disease

Neurol Sci. 2018 Mar;39(3):595-598. doi: 10.1007/s10072-017-3179-z. Epub 2017 Nov 3.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / adverse effects*
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Crohn Disease / drug therapy
  • Electromyography
  • Female
  • Gastrointestinal Diseases / etiology
  • Guillain-Barre Syndrome / chemically induced*
  • Guillain-Barre Syndrome / therapy*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Neural Conduction / drug effects
  • Time Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Tumor Necrosis Factor-alpha
  • Adalimumab